Information Provided By:
Fly News Breaks for June 12, 2017
CHRS
Jun 12, 2017 | 13:22 EDT
Cowen analyst Ken Cacciatore said Coherus Biosciences' CHS-1701 CRL "appears resolvable," with a delay most likely being a year. There does not seem to be any specific issue with 1701, but the FDA would like further analysis with a more refined assay to ensure the highest quality possible, the analyst wrote. Cacciatore rates Coherus a Buy with a $45 price target.
News For CHRS From the Last 2 Days
There are no results for your query CHRS